MX2024006360A - Celula t controlable por inducibilidad humana y metodo para prepararla. - Google Patents
Celula t controlable por inducibilidad humana y metodo para prepararla.Info
- Publication number
- MX2024006360A MX2024006360A MX2024006360A MX2024006360A MX2024006360A MX 2024006360 A MX2024006360 A MX 2024006360A MX 2024006360 A MX2024006360 A MX 2024006360A MX 2024006360 A MX2024006360 A MX 2024006360A MX 2024006360 A MX2024006360 A MX 2024006360A
- Authority
- MX
- Mexico
- Prior art keywords
- positivity
- cell
- human
- inducibility
- controllable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021190127 | 2021-11-24 | ||
| PCT/JP2022/043220 WO2023095801A1 (ja) | 2021-11-24 | 2022-11-22 | ヒト誘導性制御性ｔ細胞およびその作製方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006360A true MX2024006360A (es) | 2024-08-19 |
Family
ID=86539488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006360A MX2024006360A (es) | 2021-11-24 | 2022-11-22 | Celula t controlable por inducibilidad humana y metodo para prepararla. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250018033A1 (https=) |
| EP (1) | EP4438722A4 (https=) |
| JP (3) | JP7572755B2 (https=) |
| KR (1) | KR20240116751A (https=) |
| CN (1) | CN118591619A (https=) |
| CA (1) | CA3239019A1 (https=) |
| MX (1) | MX2024006360A (https=) |
| TW (1) | TW202330911A (https=) |
| WO (1) | WO2023095801A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024006370A (es) * | 2021-11-24 | 2024-08-19 | Regcell Co Ltd | Composicion farmaceutica para tratar o prevenir trastornos relacionados con celulas t. |
| KR20250140618A (ko) * | 2023-02-08 | 2025-09-25 | 레그셀 가부시키가이샤 | 천포창을 치료 또는 예방하기 위한 의약 조성물 |
| JPWO2024204553A1 (https=) * | 2023-03-29 | 2024-10-03 | ||
| CN116640728B (zh) * | 2023-07-24 | 2023-10-20 | 呈诺再生医学科技(北京)有限公司 | RO8191和AS2863619在诱导产生表达成人型β珠蛋白的脱核红细胞中的应用 |
| JP2025064863A (ja) * | 2023-10-06 | 2025-04-17 | 株式会社マイオリッジ | Ｔ細胞の培養方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| EA027531B1 (ru) | 2011-09-13 | 2017-08-31 | Игорь Ронинсон | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-κB |
| KR20150023223A (ko) | 2012-02-02 | 2015-03-05 | 세넥스 바이오테크놀러지 인코포레이티드 | Ｃｄｋ8/ｃｄｋ19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도 |
| RU2015107550A (ru) | 2012-08-23 | 2016-10-10 | Ф. Хоффманн-Ля Рош Аг | Новые фенилпиридин/пиразинамиды для лечения рака |
| WO2014063778A1 (en) | 2012-10-08 | 2014-05-01 | Merck Patent Gmbh | 2-aminopyridine compounds |
| GB201220157D0 (en) | 2012-11-08 | 2012-12-26 | Selvita Sa | Substitute tricyclic benzimidazoles as kinase inhibitors |
| HK1213544A1 (zh) | 2012-12-10 | 2016-07-08 | 霍夫曼-拉罗奇有限公司 | 新型二环苯基-吡啶/吡嗪用於治疗癌症 |
| WO2014106606A1 (en) | 2013-01-05 | 2014-07-10 | F. Hoffmann-La Roche Ag | Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer |
| WO2014123900A1 (en) | 2013-02-05 | 2014-08-14 | Sirenas Marine Discovery | Anti-cancer and anti-hiv compounds |
| WO2014154723A1 (en) | 2013-03-29 | 2014-10-02 | F. Hoffmann-La Roche Ag | Novel pyrrole derivatives for the treatment of cancer |
| WO2014194245A2 (en) | 2013-05-31 | 2014-12-04 | Nimbus Iris, Inc. | Cdk8 inhibitors and uses thereof |
| TW201605857A (zh) | 2013-10-03 | 2016-02-16 | 赫孚孟拉羅股份公司 | Ｃｄｋ８之醫療性抑制劑及其用途 |
| AU2014369834B2 (en) | 2013-12-24 | 2018-12-20 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| WO2015144290A1 (en) | 2014-03-27 | 2015-10-01 | Merck Patent Gmbh | Pyridyl piperidines |
| JP6529085B2 (ja) | 2014-04-18 | 2019-06-12 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6521387B2 (ja) | 2014-04-18 | 2019-05-29 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| JP2017522324A (ja) | 2014-07-17 | 2017-08-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用 |
| US11365392B2 (en) * | 2016-08-05 | 2022-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ex vivo generation of MHCII restricted CD4+ FOXP3+ regulatory T cells and therapeutic uses thereof |
| CA3051469A1 (en) * | 2017-01-27 | 2018-08-02 | Abraham J And Phyllis Katz Cord Blood Foundation | T cells derived from umbilical cord blood |
| CN114921468A (zh) | 2017-01-30 | 2022-08-19 | 国立大学法人京都大学 | 新型化合物以及调节性t细胞的制造方法 |
| US20210238551A1 (en) * | 2018-08-22 | 2021-08-05 | Osaka University | Method for Generating Regulatory T Cells |
| WO2020102321A1 (en) * | 2018-11-13 | 2020-05-22 | Abraham J And Phyllis Katz Cord Blood Foundation | T cells with improved mitochondrial function |
| EP3891270A1 (en) * | 2018-12-07 | 2021-10-13 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes |
| JP7763666B2 (ja) * | 2019-06-24 | 2025-11-04 | アムジェン インコーポレイテッド | 癌治療のためのＳＩＲＰγの阻害 |
| US20250243272A1 (en) * | 2019-11-08 | 2025-07-31 | Good T Cells, Inc. | Epitope of regulatory t cell surface antigen, and antibody specifically binding thereto |
| JP2023525298A (ja) * | 2020-05-08 | 2023-06-15 | エレクトラ・セラピューティクス・インコーポレイテッド | Ｓｉｒｐアルファおよびｓｉｒｐベータ１抗体、ならびにそれらの使用 |
| US20210374678A1 (en) | 2020-05-29 | 2021-12-02 | Delta Pds Co., Ltd. | Kanban-based work processing device and work processing method |
| KR20230019157A (ko) * | 2020-06-01 | 2023-02-07 | 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 | 유도 조절 t 세포, 이의 제조 방법, 및 용도 |
| MX2024006370A (es) * | 2021-11-24 | 2024-08-19 | Regcell Co Ltd | Composicion farmaceutica para tratar o prevenir trastornos relacionados con celulas t. |
| EP4532697A2 (en) * | 2022-06-03 | 2025-04-09 | Beam Therapeutics Inc. | Modified regulatory t cells and methods of using the same |
| EP4596684A1 (en) * | 2022-09-26 | 2025-08-06 | Regcell Co., Ltd. | Induced regulatory t cells containing chimeric antigen receptor (car) |
-
2022
- 2022-11-22 US US18/713,026 patent/US20250018033A1/en active Pending
- 2022-11-22 CN CN202280078081.XA patent/CN118591619A/zh active Pending
- 2022-11-22 WO PCT/JP2022/043220 patent/WO2023095801A1/ja not_active Ceased
- 2022-11-22 EP EP22898584.2A patent/EP4438722A4/en active Pending
- 2022-11-22 MX MX2024006360A patent/MX2024006360A/es unknown
- 2022-11-22 CA CA3239019A patent/CA3239019A1/en active Pending
- 2022-11-22 TW TW111144627A patent/TW202330911A/zh unknown
- 2022-11-22 JP JP2023528269A patent/JP7572755B2/ja active Active
- 2022-11-22 KR KR1020247020228A patent/KR20240116751A/ko active Pending
-
2024
- 2024-10-04 JP JP2024175273A patent/JP7759136B2/ja active Active
-
2025
- 2025-10-03 JP JP2025167219A patent/JP2026009980A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023095801A1 (ja) | 2023-06-01 |
| KR20240116751A (ko) | 2024-07-30 |
| EP4438722A1 (en) | 2024-10-02 |
| TW202330911A (zh) | 2023-08-01 |
| JP2025004140A (ja) | 2025-01-14 |
| EP4438722A4 (en) | 2025-10-22 |
| JPWO2023095801A1 (https=) | 2023-06-01 |
| JP7759136B2 (ja) | 2025-10-23 |
| JP7572755B2 (ja) | 2024-10-24 |
| CN118591619A (zh) | 2024-09-03 |
| JP2026009980A (ja) | 2026-01-21 |
| US20250018033A1 (en) | 2025-01-16 |
| CA3239019A1 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006360A (es) | Celula t controlable por inducibilidad humana y metodo para prepararla. | |
| CY1124717T1 (el) | Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων | |
| CY1123497T1 (el) | Συστηματα που παρεχουν μiκροσκοπικες εικονες τουλαχιστον μιας ανατομικης δομης σε μια συγκεκριμενη αναλυση | |
| MX2019013184A (es) | Dominios de union a anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso. | |
| CO2021001064A2 (es) | Método para la producción de las células t gamma delta | |
| MX2020009272A (es) | Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos. | |
| BR112019016672A8 (pt) | Método para gerar progenitores de células t | |
| MX2024006370A (es) | Composicion farmaceutica para tratar o prevenir trastornos relacionados con celulas t. | |
| EP4513175A3 (en) | Optical systems and methods for biological analysis | |
| AR085409A1 (es) | Firmas microbianas como indicadores de exposicon a radiacion | |
| WO2020061251A8 (en) | High throughput method and system for mapping intracellular phase diagrams | |
| MX2021015620A (es) | Célula para resistir reacción al trasplante y método. | |
| MX2020001920A (es) | Metodos de inactivacion de contaminantes virales. | |
| BR112015027553A2 (pt) | cartucho de imageamento, pipeta e método de uso para microscopia de esfregaço de expectoração direta | |
| MX2022016266A (es) | Metodos y sistemas para pruebas no destructivos (pnd) con procesamiento basado en inteligencia artificial entrenada. | |
| UY40565A (es) | Inhibidores de la PCSK9 y métodos de uso de los mismos | |
| MX2021015698A (es) | Integración dirigida de configuraciones aleatorias de ácidos nucleicos. | |
| MX2013010997A (es) | Ensayo para clasificacion de compuestos que disminuyen selectivamente el numero de celulas madre de cance. | |
| CR20220288A (es) | Anticuerpos contra integrina alfa 11 beta 1 | |
| EP4242429A3 (en) | Computer implemented method for monitoring a combustor in a gas turbine engine and non-transitory computer readable medium | |
| CU23896B1 (es) | Método para inhibir la replicación del vih en células de mamíferos | |
| ES2537121T3 (es) | Identificación del tropismo celular de virus | |
| Hart et al. | Is any explanation better than no explanation? Intolerance of uncertainty and paranormal beliefs | |
| CO2024003965A2 (es) | Iniciar una transmisión de una pequeña cantidad de datos basada en una o más condiciones específicas del tipo de dispositivo | |
| MX2020005562A (es) | Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1. |